374 related articles for article (PubMed ID: 31706250)
1. Gestational buprenorphine exposure: Effects on pregnancy, development, neonatal opioid withdrawal syndrome, and behavior in a translational rodent model.
Wallin CM; Bowen SE; Roberge CL; Richardson LM; Brummelte S
Drug Alcohol Depend; 2019 Dec; 205():107625. PubMed ID: 31706250
[TBL] [Abstract][Full Text] [Related]
2. Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome.
Tobacyk J; Parks BJ; Salazar P; Coward LU; Berquist MD; Gorman GS; Brents LK
Drug Alcohol Depend; 2023 Aug; 249():110832. PubMed ID: 37385117
[TBL] [Abstract][Full Text] [Related]
3. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
Wachman EM; Saia K; Miller M; Valle E; Shrestha H; Carter G; Werler M; Jones H
Clin Ther; 2019 Sep; 41(9):1681-1689. PubMed ID: 31358302
[TBL] [Abstract][Full Text] [Related]
4. Neonatal opioid toxicity: opioid withdrawal (abstinence) syndrome with emphasis on pharmacogenomics and respiratory depression.
Baldo BA
Arch Toxicol; 2023 Oct; 97(10):2575-2585. PubMed ID: 37537419
[TBL] [Abstract][Full Text] [Related]
5. Perinatal morphine but not buprenorphine affects gestational and offspring neurobehavioral outcomes in mice.
Smith BL; Hassler A; Lloyd KR; Reyes TM
Neurotoxicology; 2023 Dec; 99():292-304. PubMed ID: 37981055
[TBL] [Abstract][Full Text] [Related]
6. Care-by-parent model as a tool for reduction of neonatal opioid withdrawal syndrome in neonates exposed to buprenorphine maintenance therapy in-utero.
Lawlor ML; Shook LA; McQuerry K; Srinivasan A; Johnson QB; Chavan NR; Critchfield AS
J Matern Fetal Neonatal Med; 2020 Aug; 33(16):2718-2722. PubMed ID: 30563376
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
8. In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome.
Griffin BA; Caperton CO; Russell LN; Cabanlong CV; Wilson CD; Urquhart KR; Martins BS; Zita MD; Patton AL; Alund AW; Owens SM; Fantegrossi WE; Moran JH; Brents LK
J Pharmacol Exp Ther; 2019 Jul; 370(1):9-17. PubMed ID: 31028107
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA
J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors Associated with the Occurrence of Neonatal Opioid Withdrawal Syndrome: A Review.
Kelty E; Preen DB
CNS Drugs; 2019 Nov; 33(11):1113-1120. PubMed ID: 31686408
[TBL] [Abstract][Full Text] [Related]
12. Prenatal buprenorphine exposure and neonatal neurobehavioral functioning.
Velez ML; McConnell K; Spencer N; Montoya L; Tuten M; Jansson LM
Early Hum Dev; 2018 Feb; 117():7-14. PubMed ID: 29223912
[TBL] [Abstract][Full Text] [Related]
13. Association between Individual versus Community-level Social Vulnerability and Neonatal Opioid Withdrawal Syndrome among Pregnant Individuals Receiving Buprenorphine for Opioid Use Disorder.
Mason I; Abdelwahab M; Stiles A; Wu J; Venkatesh KK; Rood KM
Am J Perinatol; 2024 May; 41(S 01):e3157-e3163. PubMed ID: 37890511
[TBL] [Abstract][Full Text] [Related]
14. Clearance of buprenorphine during pregnancy and neonatal outcomes.
Coker JL; Ray-Griffith SL; McLeod C; Han X; Mancino M; Kearns GL; Stowe ZN
Arch Womens Ment Health; 2021 Dec; 24(6):933-939. PubMed ID: 33864131
[TBL] [Abstract][Full Text] [Related]
15. Maternal care behavior and physiology moderate offspring outcomes following gestational exposure to opioids.
Myers AM; Bowen SE; Brummelte S
Dev Psychobiol; 2023 Dec; 65(8):e22433. PubMed ID: 38010303
[TBL] [Abstract][Full Text] [Related]
16. Maternal Opioid Exposure Culminates in Perturbed Murine Neurodevelopment and Hyperactive Phenotype in Adolescence.
Schlagal CR; Dunn TJ; Xu P; Felsing DE; Merritt CR; Manja S; Fox RG; Buffington SA; Saade G; Dineley KT; Yu Y; Cunningham KA; Wu P
Neuroscience; 2021 May; 463():272-287. PubMed ID: 33811940
[TBL] [Abstract][Full Text] [Related]
17. Maternal and infant outcomes following third trimester exposure to marijuana in opioid dependent pregnant women maintained on buprenorphine.
O'Connor AB; Kelly BK; O'Brien LM
Drug Alcohol Depend; 2017 Nov; 180():200-203. PubMed ID: 28917206
[TBL] [Abstract][Full Text] [Related]
18. Maternal continuous oral oxycodone self-administration alters pup affective/social communication but not spatial learning or sensory-motor function.
Zanni G; Robinson-Drummer PA; Dougher AA; Deutsch HM; DeSalle MJ; Teplitsky D; Vemulapalli A; Sullivan RM; Eisch AJ; Barr GA
Drug Alcohol Depend; 2021 Apr; 221():108628. PubMed ID: 33761428
[TBL] [Abstract][Full Text] [Related]
19. Prenatal methadone exposure disrupts behavioral development and alters motor neuron intrinsic properties and local circuitry.
Grecco GG; Mork BE; Huang JY; Metzger CE; Haggerty DL; Reeves KC; Gao Y; Hoffman H; Katner SN; Masters AR; Morris CW; Newell EA; Engleman EA; Baucum AJ; Kim J; Yamamoto BK; Allen MR; Wu YC; Lu HC; Sheets PL; Atwood BK
Elife; 2021 Mar; 10():. PubMed ID: 33724184
[TBL] [Abstract][Full Text] [Related]
20. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL
Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871
[No Abstract] [Full Text] [Related]
[Next] [New Search]
